Computer-based simulation methods are reshaping how scientists design nanoparticle formulations for targeted cancer drug delivery, according to a critical review published in Clinical and Experimental Medicine. The review, authored by Ipshita Das, Maryam Abdul Ajees, Pawas Kumar, Yashaswini Reddy and Babitha Kampa Sundara, examines the growing role of in silico tools in the rational design, screening and optimisation of nanomedicines for oncology.
The authors argue that simulation-based methodologies offer an economic and efficient means of designing and optimising drug delivery systems. According to the review, this computational scaffolding has become essential as interest grows in nanoformulations that could increase the delivery, bioavailability and therapeutic efficacy of anticancer drugs.
The review catalogues the principal computational approaches now applied in the field, including molecular dynamics simulations, molecular docking, machine learning and artificial intelligence-based platforms. Molecular docking is described as a way to reveal ligand–nanoparticle–receptor binding mechanisms, while molecular dynamics simulations are used to decode nanoparticle behaviour under physiological and tumour conditions. AI-driven modelling, the authors note, can accelerate predictions of nanoparticle efficacy and biocompatibility, and integrated ADMET tools can streamline early screening of nanoformulated anticancer drugs.
Beyond methodology, the paper surveys specific software and platforms used in computational nanoformulation research. These include GROMACS for molecular dynamics, AutoDock for docking studies, and the commercial packages Schrödinger and Gaussian, alongside web-based tools such as SwissADME and pkCSM for pharmacokinetic and drug-likeness assessment. Together, the authors contend, these tools facilitate the design of efficient and targeted drug delivery systems and support their eventual clinical translation.
A significant portion of the review is devoted to personalised medicine. The authors describe computational methodologies as essential to the design of patient-specific therapies, because they can help reduce the systemic toxicity and side effects associated with conventional cancer treatments. The integration of in silico methods into drug nanoformulation research is characterised as a meaningful step toward more efficient, patient-specific therapy in precision oncology.
The review is equally candid about the obstacles standing between computational promise and clinical reality. The authors identify limited model validation, biological complexity, protein corona formation, the lack of specific ADMET prediction tools for nanomaterials, and regulatory uncertainty as key challenges hindering clinical translation.
As a review article, the paper synthesises existing literature rather than presenting new experimental data, and its assessments of tool performance reflect the authors’ critical appraisal of the field. The article was published open access on 15 October 2026 and is currently available as a peer-reviewed accepted version that will be replaced by the final Version of Record. The authors frame their synthesis as an illustration of the potential of in silico research to advance the development of cancer treatments using nanoformulations.
The review arrives amid broader interest in computational nanomedicine, with recent related publications covering multi-scale modelling in nano-cancer drug delivery and the role of AI and machine learning in the field. For researchers working at the intersection of nanotechnology and oncology, the authors’ central message is that computational tools, used together, can shorten the path from nanoformulation concept to clinically testable candidate, provided the field addresses validation and regulatory gaps.
Subject of Research: In silico computational tools for designing nanoparticle-based drug delivery systems in precision oncology
Article Title: Advancing precision oncology: a critical review of in Silico tools for nanoparticle-based drug delivery systems
Article References: Das, I., Ajees, M. A., Kumar, P., Reddy, Y., & Sundara, B. K. (2026). Advancing precision oncology: a critical review of in Silico tools for nanoparticle-based drug delivery systems. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-026-02348-4
Image Credits: AI Generated
DOI: 10.1007/s10238-026-02348-4
Keywords: in silico, nanoparticles, drug delivery, precision oncology, molecular dynamics, molecular docking, machine learning, artificial intelligence, ADMET, nanoformulation, cancer therapy, personalised medicine
News Source: Nathaniel Bowman. (October 29, 2026). Computational Tools Take Center Stage in Designing Nanoparticle Cancer Drug Delivery. Scienmag.
